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Abstract 
Objectives: Several models have been developed to predict mortality in ischaemic stroke.  We 
aimed to evaluate systematically the performance of published stroke prognostic scores. 
Methods: We searched MEDLINE and EMBASE in February 2014 for prognostic models 
(published between 2003-2014) used in predicting early mortality (< 6 months) after ischaemic 
stroke. We evaluated discriminant ability of the tools through meta-analysis of the area under the 
curve receiver operating characteristic (AUC) or c-statistic. We evaluated the following 
components of study validity: collection of prognostic variables, neuroimaging, treatment 
pathways, and missing data. 
Results: We identified 18 articles (involving 163 240 patients) reporting on the performance of 
prognostic models for mortality in ischaemic stroke, with 15 articles providing AUC for meta-
analysis. Most studies were either retrospective, or posthoc analyses of prospectively collected 
data; all but three reported validation data. The iSCORE had the largest number of validation 
cohorts (five) within our systematic review and showed good performance in four different 
countries, pooled AUC 0.84 (95% CI 0.82 – 0.87). We identified other potentially useful 
prognostic tools that have yet to be as extensively validated as iSCORE. - these include SOAR (2 
studies, pooled AUC 0.79, 95% CI 0.78-0.80), GWTG (2 studies, pooled AUC 0.72, 95% CI 
0.72-0.72) ) and PLAN (1 study, pooled AUC 0.85, 95% CI 0.84 – 0.87). 
Conclusions: Our meta-analysis has identified and summarized the performance of several 
prognostic scores with modest to good predictive accuracy for early mortality in ischaemic 
stroke, with the iSCORE having the broadest evidence base. 
 
Key words: Mortality; Prognostic scores; Risk prediction model; Stroke 
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Introduction 
Strokes are one of the leading causes of mortality and morbidity world-wide.  Annually, 15 
million people worldwide suffer a stroke; of these, 5 million die and another 5 million are left 
permanently disabled. (1) Mortality from stroke is particularly prominent in the first 30 days 
following the event. (2) A number of studies in recent years have focused on deriving and 
validating prognostic scores for early mortality after ischaemic stroke in the acute setting, (3-5) 
with one study demonstrating that prognostic scoring had substantially greater predictive 
accuracy than physicians’ judgments. (6) Availability of reliable prognostic tools could improve 
clinical care, guide shared decision-making and enhance communication between clinicians and 
patients. The possibility of matching patients according to prognostic score also enables stroke 
physicians to do comparative evaluations of different models of stroke care, whether as part of 
quality improvement projects or clinical trials. However, absence of uniformly accepted 
prognostic tool amongst the myriad of options is an important barrier. 
We are not aware of any recent meta-analyses of stroke prognosis tools, but there has been a 
previous systematic review published by Counsell in 2001. (7) This systematic review critically 
appraised 83 separate prognostic models and identified serious deficiencies in the statistical 
validity, generalizability and validity of the evidence at that time.  There has since emerged a 
plethora of publications reporting on different stroke prognosis scores. (4, 5, 8-10) 
Hence, we aimed to synthesize recent evidence on prognostic models in patients presenting 
acutely with ischaemic strokes, and to assess comparative performance of different scores so that 
clinicians and researchers can make informed decisions on use of such tools. 
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Methods 
Eligibility criteria 
We selected studies that used clinical variables (or groups of variables) in multivariate clinical 
prognostic models for overall mortality (< 6 months) in adult patients presenting with stroke. 
Eligible studies had to have a majority of participants with ischaemic stroke, with reporting of 
test performance through sensitivity/ specificity or area under receiver operating characteristic 
(AUC) or c-statistic. As our main aim was to produce a synthesis of up to date evidence, we 
restricted our selection to studies published from 2003 onwards. 
We excluded studies that were designed solely to correlate mortality with laboratory (e.g. 
albumin, white cell count, copeptin, etc.) or radiological variables (such as size of lesion). We 
did not consider studies that reported only on functional outcomes, or were based only on 
patients requiring intensive care. As our main focus was on stroke patients presenting to 
healthcare facilities, we excluded studies that focused on mortality in specific subsets of patients 
e.g. following a particular intervention (i.e. after thrombolysis or thrombectomy), or those that 
specifically examined stroke in a particular brain area (e.g. thalamic, or basilar).  
Search strategy 
We searched MEDLINE and EMBASE (OvidSP interface, February 2014) using the search 
terms listed in Supplementary Material 1, without any language restriction. We also checked the 
bibliographies of included studies for any potentially suitable studies. 
Study selection and data extraction 
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We allocated study screening and data extraction to pairs of reviewers (KM, CSK, KP, AM, 
YKL) who independently scanned all titles and abstracts for potentially relevant articles, before 
proceeding to obtain full text versions for further checking. Any uncertainties and discrepancies 
were resolved through discussion and with a third reviewer. We also contacted authors if there 
were any areas that required further clarification.  
We used a standardized form for data collection which included details on the setting, date of 
study, country of origin, selection criteria, participant characteristics, and outcome measures. 
Assessment of Study Validity 
For the assessment of study validity, pairs of reviewers independently checked whether there was 
clear reporting of neuroimaging, time of patient assessment, missing or incomplete data, and 
treatment protocols.  
Data analysis 
We focused on the Area under the Receiver Operating Curve (AUC) or c-statistic (which are 
equivalent measures of the discriminant ability for binary outcomes). (11) Here, the discriminant 
ability reflects how well the model separates patients who die during follow-up as opposed to 
those who survive. For studies that reported on both derivation and validation components, we 
chose to analyze data relating to the validation portion. If different mortality time-points were 
reported in a single study, we focused on 30-day as the first choice, inpatient mortality as the 
second choice, and where neither were available, we accepted a time point (< 6 months) for 
analysis. If a number of AUC values were available for a particular prognostic tool, we 
calculated a weighted pooled average using random effects inverse variance meta-analysis. If the 
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AUCs were listed without standard errors, we imputed these values from the 95% confidence 
intervals or through Hanley’s method. (12) 
We assessed heterogeneity through the I2 statistic and visual inspection of the Forest plots. The 
performance of the prognostic score was judged according to AUC thresholds that have been 
described by other researchers: excellent (AUC≥0.90), good (AUC≥0.80 and <0.90), fair 
(AUC≥0.70 and <0.80) and poor (AUC <0.70). (13) 
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Results 
We included 18 relevant studies from 2374 hits that were retrieved through the electronic 
database search. (3-5, 8-10, 14-25) The flow chart of study selection is shown in Figure 1.  
Characteristics and results of the included studies are shown in Supplementary Table A1, while 
assessment of study validity is reported in Supplementary Table A2.   
The included studies had a total of 163240 participants (sample sizes from 75 – 109995), with 
mean age 71 years, while 54% of the participants were male. There were 10 multi-centre studies 
that recruited patients from more than two healthcare sites. (3-5, 8-10, 18, 19, 22, 25) 
Geographical locations were diverse, and included North America, Europe, Egypt and Asia. All 
the studies evaluated score validation, except for three that were mainly derivation studies. (8, 
19, 23) 
 
Validity assessment 
As the majority of studies were retrospective in design, or posthoc analyses of prospectively 
collected clinical data, we were seldom able to judge if the prognostic variables were collected 
early in the course of the presentation. Treatment pathways were seldom reported, with only 
three studies explicitly stating that participants received similar care. (14, 18, 19) We recorded 
more complete reporting of the modality used in neuroimaging (12 studies), as well as amount of 
missing data (10 studies). (Supplementary Table A2) In view of the lack of detail in 
methodological reporting, we have not attempted to categorize studies into either a high or low 
quality subgroup. 
 
Quantitative comparison of AUC 
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We were able to evaluate the following prognostic models in the comparative quantitative 
analysis: iSCORE (five cohorts in four articles) (4, 14, 16, 22), NIHSS (three cohorts), GWTG 
(two cohorts), (5, 15, 25) Essen Stroke Risk Score (two cohorts), (18, 20) SOAR (2 cohorts) (3, 
8) and PLAN (one cohort). (9) 
The AUCs from individual studies, as well as pooled mean AUC across studies (and 
heterogeneity statistic) are shown in Figure 2. A summary of the information required in the 
calculation of each prognostic tool is available in Supplementary Table 3. 
 
iSCORE 
The performance of the iSCORE in predicting 30-day mortality has been evaluated in five 
cohorts with a total of 12833 participants from Canada, France, Greece and Korea. (4, 14, 16, 22) 
Point estimates of the AUC ranged from 0.79 to 0.86, with a weighted pooled average of 0.84 
(0.82 – 0.87). 
 
NIHSS 
The performance of the NIHSS was reported in three cohorts with a total of 50864 participants 
from India (30-day mortality), North America and China (both focusing on inpatient mortality). 
(5, 15, 25) Point estimates of the AUC ranged from 0.83 to 0.89, with a weighted pooled average 
of 0.85 (0.82 – 0.88). 
 
Essen Stroke Risk Score (ESRS) 
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The performance of the ESRS in predicting 90-day or inpatient mortality was reported in two 
cohorts with a total of 7570 participants from multiple centres. (18, 20) Point estimates of the 
AUC were identical in both studies, and yielded a weighted pooled average of 0.71 (0.69 – 0.72). 
 
GWTG, with or without NIHSS 
There were two studies reporting on the performance of the GWTG score on its own for 
predicting inpatient mortality. (5, 25) The studies enrolled at total of 117010 participants in 
North America and China. Both studies demonstrated consistent findings for the GWTG, with a 
weighted pooled average AUC of 0.72 (0.72 – 0.72). When the GWTG was considered together 
with NIHSS, the pooled AUC was markedly improved to 0.85 (0.84 – 0.87). 
 
SOAR 
The performance of the SOAR score with regards to predicting inpatient mortality was evaluated 
in two UK cohorts with a total of 15902 participants. Point estimates of the AUC ranged from 
0.79 to 0.80, with a weighted pooled average of 0.79 (0.78 – 0.80). (3, 8) 
 
PLAN 
We identified only one study reporting on the PLAN score. (9) This study recruited 4904 
participants in Canada and reported an AUC of 0.87 (0.85-0.88) for those who were not 
thrombolysed, and 0.72 (0.69- 0.75) for those who were thrombolysed. We estimated a weighted 
pooled average AUC of 0.85 (0.84-0.87) for the whole cohort. 
 
Prognostic scores with AUC from single cohorts not included in comparative meta-analysis 
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We identified only one study reporting on the prognostic value of the GCS. This study recruited 
1217 participants in Scotland and reported an AUC of 0.78 (0.75-0.81). (24) 
Roquer et al. evaluated the prognostic value of the VRS II in 1527 patients in Spain and found an 
AUC of 0.71 (0.67-0.75) for inpatient mortality. (23) 
In addition to testing the ESRS, Maier et al. also studied the RRE-90 and ABCD scores in 
predicting inpatient mortality, with respective AUCs of 0.64 (0.56–0.73) and 0.66 (0.59-
0.73) (20) 
Finally, one study reported an AUC of 0.73 without 95% confidence intervals for the Six 
Simple Variable model. (19) 
 
Studies not suitable for quantitative AUC analysis 
Three studies reported only on sensitivity and specificity of the prognostic model. (10, 17, 21) 
There were two studies that enrolled small sample sizes (<100 patients) in single centres, which 
means that the data may have limited generalizability or applicability. El Sheikh et al. reported 
on the APACHE III score in 93 patients in Egypt and found a sensitivity of 0.89 and specificity 
of 0.70 for 30-day mortality. (17) Martinsson et al. evaluated 90-day  mortality with the Barthel 
Index and Activities of Daily Living in 75 patients in Stockholm and reported a sensitivity of 
0.81 and specificity of 0.53 for a Barthel Index of >10. (21) 
A multicenter study of 1217 patients in Germany for the purposes of deriving and validating the 
ESRS found a sensitivity of 0.58 and specificity of 0.92 based on the threshold of 0.289 for the 
score. (10) 
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Discussion 
Although the prediction of mortality in ischaemic stroke is complex, our review has identified 
several promising developments with moderate to good performance that can help clinicians and 
researchers decide which score to use.  One of the frontrunners is the iSCORE.  This prognostic 
model has the largest number of validation studies within our systematic review and has been 
tested in different countries (Canada, France, Greece and Korea) with consistently good results. 
(4, 14, 16, 22) An important barrier to the use of iSCORE by non-specialists is the need to 
calculate a neurological subscale, either the Canadian Neurological Scale (CNS) or NIHSS score 
beforehand. This additional step is potentially laborious and may require additional training.  
However, it is possible to calculate the iSCORE online [http://www.sorcan.ca/iscore/] or via a 
mobile application that has some guidance on the CNS score, and there appears to be less of a 
problem with missing data items with the CNS than with NIHSS. (26) 
A further point to consider in relation to the iSCORE is that if the NIHSS score is already 
available, then that alone may be sufficient to provide prognostic accuracy similar to that of the 
iSCORE.  We found that the NIHSS score has been reported in three cohorts from India, North 
America and China with a very similar weighted pooled average AUC (good predictive 
accuracy) to the iSCORE. Nevertheless, we also recognize that NIHSS scoring can be complex 
for non-specialists or difficult to obtain (missing in 60% of participants from a North American 
cohort), (5)and there are problems with inter-rater reliability. (26) 
Based on the pooled average AUC, we would consider the GWTG and SOAR scores to have 
moderate performance in predicting mortality after ischaemic stroke; the major advantage being 
ease of use by non-specialists because neither of GWTG nor SOAR requires use of neurological 
severity subscales such as the NIHSS.  However, each of these scores has been evaluated in only 
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two studies and we feel that there is a need to validate these further; a direct comparison with the 
iScore would be desirable.  It is also important to note that one of the elements needed for the 
SOAR score is the Oxford Community Stroke Project classification (OCSP), which requires 
greater depth of knowledge, and may not always correlate well with findings on brain imaging. 
(27) There are issues arising from variation in inter-rater reliability with the OCSP and modified 
Rankin score (both of which are components of SOAR), (28) thus potentially leading to 
inconsistent estimates in the final score .  An advantage of the GWTG score is that is does not 
require such pre-knowledge (of the NIHSS or OCSP for example) in order to complete it. 
However, two studies that directly compared GWTG with NIHSS found that NIHSS offered 
greater discriminant ability than GWTG alone. (5, 25) 
 
The PLAN score also has a similar weighted pooled average AUC (good predictive accuracy) 
compared to the iSCORE and NIHSS, however, we found only one study reporting it. (9)  In this 
study, the performance of PLAN in patients who received thrombolysis was weaker, for reasons 
which are as yet unclear.  It does appear to be promising though in that it only uses few clinical 
variables which can be used as a bedside assessment tool and does not need specialist pre-
knowledge of other subscales and classifications.  
 
Back in 2001, Counsell’s systematic review commented on the overall poor quality and lack of 
improvement in stroke prognosis research over a time period of two decades. (7) In comparison 
to Counsell’s findings, our updated systematic review of studies published in the last ten years 
has identified larger, more rigorous studies that may have been previously lacking. Unlike the 
previous systematic review, we were able to carry out meta-analysis that reported appropriate 
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statistical measures from a variety of validation sets.  We believe that the information from our 
systematic review will be very useful in helping researchers stratify and match patients when 
comparing mortality outcomes in observational studies of stroke care (e.g. between different 
healthcare centres, or different times of presentation such as weekends or weekdays). 
 
However, the available studies do not report on acceptability and uptake of current prognostic 
scores in the day to day management of stroke patients.  While good performance of a prediction 
rule is an important pre-requisite, patients will not gain any benefits from the profusion of 
prognostic scoring models if the uptake and implementation is patchy. There are parallels here 
with prognostic indices in community-acquired pneumonia, where an Australian survey found 
that only 12% of respiratory physicians and 35% emergency physicians reported regular use of 
the highly sensitive Pneumonia Severity Index. (29) The complexity of calculation proved 
challenging and many physicians were unable to accurately estimate the Pneumonia Severity 
Index scores. (29) Ideally, a prognostic score should be easy to use (without requiring specialist 
training or additional steps in having to calculate a subscale beforehand), memorable and 
accurate. 
   
Our systematic review has limitations.  We have focused only on research carried out over the 
last ten years and we chose not to emphasize functional outcomes because they are assessed in 
diverse ways, and determined to some extent by pre-stroke status. We aimed to specifically 
evaluate overall mortality as a hard outcome, bearing in mind findings from a recent systematic 
review where existing prognostic models in stroke had poor discriminant ability for recurrent 
stroke and myocardial infarction. (30) The majority of our included studies were retrospective, or 
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posthoc analyses of prospectively collected clinical data and we have not categorized studies into 
either high or low quality subgroups.  We selected published studies which used the AUC or c-
statistic as their primary measure; it is possible that studies that found poor discriminant ability 
may have been unpublished or unreported. The aetiology and severity of stroke can vary 
considerably across different geographical and ethnic populations, and a model that performs 
well in one hospital may perform less accurately in another setting without further re-calibration. 
We appreciate that prognostic models are imperfect, and should only be interpreted together with 
clinical information and judgment. 
 
Conclusions 
There are now a number of stroke prognostic scores showing moderate to good performance in 
predicting mortality after ischaemic stroke, and our review suggests that the iSCORE has the 
broadest supporting evidence base amongst the available prognostic tools.      
We feel that the most promising recently validated models should all be compared directly in a 
large, prospective multi-centre international cohort measuring clinician uptake and ensuring 
treatment on the same pathway. 
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Online Supplementary Material: Search Strategy 
Interface: OvidSP  
 
Databases: MEDLINE, EMBASE 
No language restrictions 
 
Search terms used with .mp suffix: stroke AND score AND (prognostic OR prognosis OR 
predicti*) AND (mortality OR death OR survival) 
For this search, .mp includes the fields of title, abstract, subject headings, heading words, 
original title, drug or device manufacturer, trade name, keyword, keyword heading word, unique 
identifier. 
We checked bibliographies of included articles for any additional relevant studies. 
We contacted authors for more information if there were any uncertainties when reviewing the 
articles. 
We used online translation tools if there were any foreign language articles that we were unable 
to translate ourselves. 
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Online Supplementary Tables 
Table A1: Characteristics of included studies 
Study ID Study setting 
and year, 
number of 
centres 
Study design, 
and name of 
score 
Patient 
population 
Patients, n Age, yr 
(mean or 
median) 
Male, 
% 
% Mortality 
at follow-up  
AUC 
Bejot 2013 (14) Dijon Stroke 
Registry, two 
centres2006-
2011 
Retrospective 
validation, 
iScore 
Acute ischaemic 
sroke 
1199 76 46 30-day: not 
stated 
30-day:0.85 (0.82-0.89) 
Birkner 2007 
(15) 
Rural hospital, 
India, 1999-
2001. 
Prospective 
cohort, 
validation of 
NIHSS 
Acute Stroke 
(66% ischaemic, 
33% 
haemorrhagic) 
175 59 62 30-day: 29% 30-day: sensitivity 0.92, 
specificity 0.65%, AUC 0.89 
(0.84-0.94). 
Dragoumanos 
2013 (16) 
Greece, tertiary 
hospital, 2008-
2011 
Prospective 
validation, 
iScore 
Acute ischaemic 
stroke 
534 75 49 30-day 30-day: 0.87 (0.80 – 0.93) 
and 0.85 (0.79 – 0.91) 
El-Sheikh 2010 
(17) 
Hospital in 
Egypt, 2007-8 
Prospective 
cohort 
validation, 
APACHE III 
Acute stroke 
within 48 hrs 
93 59 65 30-day: 18% Score >40 
Cerebral infarction: 
Sensitivity 0.89 Specificity 
0.70 
Konig 2008 (18) VISTA Data Set 
patients 
extracted from 
11 trials in 
Retrospective 
cohort 
validation, 
Ischaemic stroke 
patients in 
clinical trials 
5843 69 56 90-day:18% AUC = 0.706 (S.E. = 0.009) 
for prediction of survival 
after 3 months 
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many countries ESRS 
Kwok 2013 (3) (8 hospitals in 
Anglia Stroke & 
Heart clinical 
network), Sept 
2008 – Apr 
2011 
Retrospective, 
external 
validation 
SOAR  
Ischaemic 
(92%) and 
hemorrhagic 
stroke 
3547 Median 
around 
76-80 
years. 
51 Inpatient: 
17% 
7-day: 6% 
Inpatient mortality 0.80 (95% 
CI 0.78 – 0.82)  
7-day mortality 0.82 (95% CI 
0.79 – 0.84)  
Cutoff greater or equal to 
3::Sensitivity: 0.73 
(inpatient); Specificity: 0.76 
(inpatient) 
Lewis 2008 (19) Participant in 
International 
Stroke Trial 3  
before Feb 2007 
Six simple 
variable (SSV) 
derivation 
model 
Acute Ischaemic 
stroke patients 
in clinical trials 
537 74 54 30-day: 21% 30-day AUC 0.73 
Maier 2013 (20) Hospital, 
Germany 2007-
2011 
Retrospective 
validation, 
RRE-90 (cut-
off); ABCD; 
ESRS 
Ischaemic stroke 1727 71 56 Inpatient 
mortality: 
not stated 
7-day 
mortality: 
2.3% 
Inpatient ESRS 0.71 (0.63-
0.79); ABCD 0.66 (0.59-
0.73); RRE 0.64 (0.56-0.730 
Early death (7-day): ESRS 
0.58 (0.49 – 0.66); ABCD 
0.65 (0.58 -0.72); RRE 0.72 
(0.66-0.78) 
Martinsson 
2006 (21) 
Trial patients in 
Stockholm, 
Sweden, from 
1998 to  
2001  
Retrospective 
conort, 
validation, 
Barthel Index 
(BI), Activity 
Index (AI) 
Ischaemic stroke 
in clnical trials 
75 74 49 7-day or 90-
day mortality 
rate not 
stated 
 
7-day mortality: BI baseline 
score > 10 (sensitivity 0.76; 
specificity 0.80) and 
AI(ADL) baseline score > 15 
(sensitivity 0.58; specificity 
1.00) 
90-day mortality: BI>10 
(sensitivity 0.81; specificity 
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0.53, AI(ADL) >15 
(sensitivity 0.65; specificity 
0.75) 
Myint 2013 (8) UK, 3 hospitals 
(1997 – 2010) 
Retrospective 
derivation, 
SOAR 
Ischaemic 
(91%) and 
haemorrhagic 
stroke 
12355 Median 
around 
76-80 
years. 
47 Inpatient 
20% 
7-day 10% 
Inpatient mortality: 0·79 
(95% CI 0·78–0·80)  
7-day mortality 0·79 (95% 
CI 0·78–0·80) 
O’Donell 2012 
(9) 
Canada. 11 
centres, 
2003-2008 
Retrospective 
derivation and, 
validation 
PLAN 
Acute ischaemic 
stroke 
4904 73 52 30-day: 
13.5% 
30-day mortality: Not 
thrombolysed 0.87 (0.85 – 
0.88); Thrombolysed: 0.72 
(0.69-0.75)  
 
Park 2013 (22) 12 centres 
Korea, 2011 
Retrospective 
validation, 
iSCOre 
Acute ischaemic 
stroke 
4061 68 59 90-day 7.2% 0.861 (0.840-0.883) 
Roquer 2007 
(23) 
Hospital, Spain 
1997-2005 
Retrospective 
derivation, 
VRS II 
Acute ischaemic 
stroke 
1527 73 51 Inpatient: 
12.9% 
Inpatient: AUC 0.711 
(0.673–0.749)  
Saposnik 2011 
(4) 
Multicentre 
Canada 2003-
2008 
Retrospective 
derivation and 
validation, 
iSCORE 
Acute ischaemic 
stroke 
Int val: 
4039 
Ext val: 
3270 
Int val: 72 
Ext val: 
74 
Int val: 
52 
Ext 50 
30-day: 
12.6% (int 
validation) 
11.6% (ext 
validation 
AUC:Int validation 0.851 
(SE 0.0109) 
Ext validation: 0.792 (SE 
0.0142) 
Smith 2010 (5) Multicentre, US 
and Canada, 
Retrospective 
derivation and 
Acute ischaemic 109995 
(validatio
74 47 Inpatient: GWTG AUC overall 0.72 
(SE 0.0038) 
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2001-2007 validation, 
GWTG, 
NIHSS 
stroke n) 
NIHSS 
available: 
43674 
5.5% overall 
5.2% NIHSS 
available 
NIHSS available: 0.85 (SE 
0.0051) 
NIHSS alone: 0.83 (SE 
0.0054) 
Weimar 2004 
(10) 
Multicentre, 
Germany, 2001-
2002 
Prospective 
derivation and 
validation, 
Age and 
NIHSS 
Acute ischaemic 
stroke 
1307 
validation 
68 57 100-day: rate 
not stated 
Model II: sensitivity 0.579 
specificity 0.915 based on 
0.289 threshold 
Weir 2003 (24) Single centre, 
Scotland, 1990-
1995 
Retrospective 
validation, 
GCS 
All strokes 
(87% ischaemic) 
1217 71 49 14-day: 19% AUC 0.78 (SE 0.0188) 
Score of E+V9 Sensitivity 
0.74, Specificity 0.76 
Zhang 2012 (25) China registry 
multicenter, 
2007-2008 
Retrospective 
validation,  
NIHSS, 
GWTG 
Acute ischaemic 
stroke 
7015 68 61 In-hospital: 
2.9% 
GWTG alone: 0.735 (0.701–
0.770) 
GWTG with NIHSS 0.867 
(0.84-0.895) 
NIHSS alone  0.847 (0.816 – 
0.879) 
 
Abbreviations: BI = Barthel Index; ADL = Activities of Daily Living, GCS = Glasgow Coma Score 
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Table A2: Assessment of study validity 
Study ID Did the authors 
state that 
CT/MRI was 
done for all 
patients? 
Was the index/score 
obtained early in 
course of 
presentation? 
Did the authors 
give numbers or 
reasons on loss to 
follow-up or 
withdrawals? 
Did the authors state 
whether the patients 
were treated on a 
standardized or 
similar care pathway? 
Amount of missing data 
Bejot 2013 (14)     107 (8.9% missing) 
Birkner 2007 (15)      
Dragoumanos 
2013 (16) 
     
El-Sheikh 2010 
(17) 
     
Konig 2008 (18)      
Kwok 2013 (3)     59% of patients not eligible 
for SOAR incomplete data 
Lewis 2008 (19)      
Maier 2013 (20)      
Martinsson 2006 
(21) 
     
Myint 2013 (8)      
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O’Donell 2012 (9)     225 incomplete data 
Paark 2013 (22)     699 patients incomplete data 
Roquer 2007 (23)     163 incomplete data 
Saposnik 2011 (4)      
Smith 2010 (5)      
Weimar 2004 (10)     >200 patients incomplete data 
Weir 2003 (24)     300 patients incomplete data 
Zhang 2012 (25)     2623 + 265 NIHSS 
incomplete  
Abbreviations: CT = Computerized tomography; MRI = magnetic resonance imaging 
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Table A3: Information needed to calculate prognostic scores in Stroke 
Score 
 
Patient characteristics and past history Clinical examination Stroke 
Classifi
cation 
 Laboratory 
measures 
Other Software 
required to 
calculate 
Age Gend
er 
Risk 
Factors 
Comorbid 
conditions 
Preadmiss
ion status 
BP Temp Neurological Stroke 
Subtype 
Gluco
se 
H
b 
W
BC 
Creatini
ne 
  
iSCO
RE  
Y Y AF, MI, 
CHF, 
Smoker 
Cancer, 
Renal 
dialysis,  
Disability _ _ CNS or NIHSS Lacunar, 
Non-
lacunar, 
Unknow
n 
Y _ _ _ _ Yes (web or 
app available) 
NIHS
S 
N N _ _ _ _ _ Level of 
consciousness, 
horizontal eye 
movement, visual 
field test, facial 
palsy, motor arm, 
motor leg, limb 
ataxia, sensory 
language, 
dysarthria, 
extinction and 
inattention 
_ _ _ _ _ _ No 
GWT
G  
Y N AF, 
Previous 
stroke 
/TIA, 
carotid 
stenosis 
(>50%), 
hypertensio
n, 
dyslipidae
mia, 
Diabetes 
mellitus, 
CAD, 
PVD,  
_ _ _ _ _ _ _ _ _ Mode 
of 
arrival, 
day & 
time of 
arrival 
No 
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smoker 
SOAR  Y N _ _ Prestroke 
Rankin 
Score 
_ _ _ OSCP _ _ _ _ _ No 
PLAN Y Y Hypertensi
on, 
Hyperlipide
mia, CHF, 
MI/angina, 
AF,  
Diabetes, 
chronic 
liver 
disease, 
dementia, 
cancer 
Dependen
ce 
Y Y Weakness of the 
face, arms, and 
legs, aphasia; 
dysphagia; neglect; 
visual field deficit; 
and side of the 
symptoms 
_ _ Y Y Y _ No 
Abbreviations: AF = atrial fibrillation, MI = myocardial infarction, CHF = chronic heart failure, TIA = transient ischaemic attack, OCSP = 
Oxford Community Stroke Project  
 
 
 
